Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Amortizatization of Intangibles (2018 - 2022)

Historic Amortizatization of Intangibles for Spero Therapeutics (SPRO) over the last 5 years, with Q2 2022 value amounting to $10000.0.

  • Spero Therapeutics' Amortizatization of Intangibles rose 11666.67% to $10000.0 in Q2 2022 from the same period last year, while for Mar 2023 it was $10000.0, marking a year-over-year increase of 10476.19%. This contributed to the annual value of -$13000.0 for FY2022, which is 9482.07% up from last year.
  • Per Spero Therapeutics' latest filing, its Amortizatization of Intangibles stood at $10000.0 for Q2 2022, which was up 11666.67% from -$23000.0 recorded in Q1 2022.
  • In the past 5 years, Spero Therapeutics' Amortizatization of Intangibles registered a high of $355000.0 during Q1 2019, and its lowest value of -$73000.0 during Q3 2021.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $27500.0 (2018), whereas its average is $66055.6.
  • As far as peak fluctuations go, Spero Therapeutics' Amortizatization of Intangibles skyrocketed by 68888.89% in 2019, and later tumbled by 355000.0% in 2021.
  • Over the past 5 years, Spero Therapeutics' Amortizatization of Intangibles (Quarter) stood at $325000.0 in 2018, then tumbled by 73.23% to $87000.0 in 2019, then plummeted by 128.74% to -$25000.0 in 2020, then tumbled by 116.0% to -$54000.0 in 2021, then surged by 118.52% to $10000.0 in 2022.
  • Its last three reported values are $10000.0 in Q2 2022, -$23000.0 for Q1 2022, and -$54000.0 during Q4 2021.